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INTRODUCTION: Prostate cancer is the second most commonly diagnosed cancer in 
men. Robot Assisted Laparoscopic Prostatectomy (RALP) and External Beam 
Radiation Therapy (EBRT) are standard treatments for clinically localized prostate 
cancer, but both of these treatments have negative consequences for urinary and sexual 
function in patients. 
PURPOSE: To compare changes in urinary and sexual function for men treated with 
RALP and EBRT. 
HYPOTHESIS: It was hypothesized that patients treated with EBRT would have better 
recovery of sexual function, and patients treated with RALP would have better recovery 
of urinary function.  
METHODS: Urinary and sexual function for patients treated for prostate cancer was 
examined using EPIC questionnaires. These questionnaires were completed before 
treatment and two years after initial treatment in 32 men treated with EBRT, and 104 
men treated with RALP. The difference between initial treatment scores and 2-year 
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scores were analyzed with a GLM procedure to assess the quality of life outcomes for 
EBRT and RALP. 
RESULTS: No significant difference was found for change in urinary function for 
either treatment group (p = 0.41).  EBRT was found to significantly increase recovery 
sexual function compared to RALP (p = 0.04).  
CONCLUSION: EBRT is a better treatment for preserving sexual function in men with 
prostate cancer, and urinary function will be largely similar with either treatment.    
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Background: An Overview of Prostate Cancer  
Anatomy and Physiology of the Prostate  
The prostate is a male specific organ that encircles the urethra and borders the 
inferior aspect of the bladder. The prostate contains the ejaculatory duct, which is the 
end of the spermatic tube that extends all the way down from the testes. Sperm travel 
through this tube to get to the urethra during ejaculation. Nerves that supply the urethra 
and penis run posterior-laterally along the prostate and are contained in the 
neurovascular bundles. The function of the prostate is to create and secrete certain 
components found in semen. One of these components is prostate specific antigen 
(PSA), which is a protein that helps maintain a low viscosity in semen to allow the 
sperm to swim freely (LEE et al., 1989).  
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Illustration 1: Anatomy of the Prostate 
 (1) Ureter, (2) Vas Deferens, (3) Bladder, (4) Seminal Vesicle (5) Prostate (6) Urethra. 
Illustration by Martin Allums. 
 
Illustration 2: Neurovascular Bundles of the Prostate 
Illustration by Martin Allums 
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Prostate Cancer 
Prostate cancer is the second most frequently diagnosed cancer in the United 
States, falling only behind skin cancer (Haas et al., 2008). In a healthy functioning 
prostate the PSA that is produced is almost entirely secreted into the urethra during 
ejaculation, with only small levels leaking into blood stream circulation (Stenman et al., 
1999). When prostate cells become cancerous they rapidly proliferate and create an 
excess amount of PSA. This is more PSA than can be secreted into the urethra during 
ejaculation, and the excess is leaked into circulation and that be detected by a blood 
tests and indicate abnormal prostatic tissue growth (Smith et al., 2009). Thus, PSA 
screenings are conducted by physicians in men over 50 to look for sharp increases in 
PSA that could indicate prostate cancer (Smith et al., 2009).  
While elevated PSA levels may indicate a cancer, there are other conditions that 
can cause PSA levels to rise. Benign Prostatic Hyperplasia (BPH) is a common 
condition among men over the age of 50, and also results in elevated levels of PSA 
(Stenman et al., 1999). BPH is a condition where the prostate grows larger without 
evidence of malignancy (Stenman et al., 1999). This additional growth of prostate cells 
will also produce an excess of PSA, which will be detected in a blood test. Other 
conditions such as a bladder or prostate infection can also cause the PSA to spike. If no 
inflammation or infection is clinically apparent, then further evaluation of elevated PSA 
often includes Transrectal Ultrasound (TRUS) guided biopsy of the prostate to deduce if 
prostate cells have become cancerous (Heidenreich et al., 2008).  
A Transrectal Ultrasound (TRUS) guided biopsy takes up to 12 samples of 
prostatic tissue in each region of the prostate to test for malignancy. The samples taken 
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from the TRUS biopsy are examined and given a Gleason Score. This measures the 
histological appearance and number of cancerous prostate cells in the sample, and 
assigns them a grade from 1 to 5 (Humphrey, 2004). A grade of 1 represents cells that 
are packed closely together but are still separated with a uniform appearance and well 
differentiated growth patterns. A grade of 5 represents the most altered appearance of 
the cells with large, observable, different shaped masses (Humphrey, 2004). The grades 
2-4 represent the range of appearances of the cancer cells between the grades 1 and 5 
(Humphrey, 2004). The Gleason Score is calculated by summing the two largest grades 
assigned to the histological sample of the prostate tissue, generating a value of 2-10 
(Humphrey, 2004). Patients with a Gleason Score of 2-6 are candidates for active 
surveillance, which is essentially just close surveillance of PSA progression without 
definitive treatment to avoid over-treatment (Shah, 2009). Patients with a Gleason Score 
of 7 or greater are in need of definitive therapy (Shah, 2009).   
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Illustration 3: Transrectal Ultrasound Guided Biopsy Specimen Sites 
Illustration by Martin Allums 
Another tool used to assess the extent of the cancer is the Tumor-Node-
Metastasis (TNM) staging system. The TNM cancer staging system is used to assign a 
stage to cancerous prostatic samples (Edge & Compton, 2010). The TNM outlines the 
location of the cancer in relation to the prostate gland and the rest of the body. The letter 
T in the TNM score denotes that there is a tumor in the prostate. The letter N in the 
TNM score signifies a tumor in a lymph node, and the letter M indicates metastasis in 
other locations in the body. A common score is T2a, which indicates a tumor involving 
one half a prostatic lobe or less. The TNM staging can be diagnosed from a TRUS 
biopsy, or by palpation of the prostate via rectal exam (Edge & Compton, 2010).  
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Treatment of Prostate Cancer 
Definitive Treatment Options 
Surgical removal of the prostate is a common procedure used to treat prostate 
cancer. The surgical techniques of prostatectomies have evolved in the last two decades 
from the traditional Radical Retropubic Prostatectomy (RRP) which was considered the 
gold standard treatment for prostate cancer (Coelho et al., 2010). A RRP is an invasive 
procedure which involves a large open incision in the abdomen and surgical dissection 
of the prostate (Barré, 2007). New surgical techniques have developed such that 
laparoscopic dissection (a minimally invasive procedure with a few small incisions) of 
the prostate can be achieved with the assistance of a da Vinci Robotic Surgical System. 
This new technology allows surgeons to perform a Robot Assisted Laparoscopic 
Prostatectomy (RALP) with minimal invasion compared to the open incision of the 
RRP. RALP operations can be performed as Nerve Sparing (NS) procedures, where the 
neurovascular bundles are dissected away from the prostate in an attempt to preserve 
the urinary and sexual function of the patient (Coelho et al., 2010). As there is a 
neurovascular bundle that runs on both sides of the prostate, a NS procedure can be 
bilateral where both neurovascular bundles are dissected away, or unilateral if only one 
is dissected away. The type of NS procedure depends on the girth and location of the 
tumor, if the tumor extends into the regions of these neurovascular bundles they will not 
be dissected away in an attempt to remove all cancerous cells (Talcott et al., 1997). 
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Illustration 4: Surgical Incision Sites for RALP 
Illustration by Martin Allums 
External Beam Radiation Therapy is another common treatment for prostate 
cancer. EBRT is radiation delivered from an external source directed at the prostate 
from different angles to preserve the tissue around the prostate (Heidenreich et al., 
2008). If a patient has received a prostatectomy as initial treatment and there is 
reoccurrence of prostate cancer, they can go on to receive EBRT (Heidenreich et al., 
2008). However, once a patient receives EBRT for their initial treatment, they have 
received a lifetime dose of radiation to that area and are not able to undergo any more 
radiation treatment for their prostate cancer (Heidenreich et al., 2008). 
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Another treatment for prostate cancer is Androgen Deprivation Therapy (also 
referred to as hormone therapy). The growth of most prostate cancer cells is dependent 
on androgens (sex hormones), most often testosterone or dihydrotestosterone 
(Miyamoto et al., 2004). To treat prostate cancer, hormone deprivation therapy aims to 
stop the production of testosterone. This is achieved by either pharmaceutically or 
surgically castrating the patient, or stopping the body’s natural production of androgens 
(Miyamoto et al., 2004). Androgen deprivation therapy is not a curative treatment, it is 
used to slow the disease progression and extend patient life (Miyamoto et al., 2004). 
This therapy is often given to patients who have failed initial treatment of RALP or 
EBRT who’s disease has spread to other areas of the body (Heidenreich et al., 2008). 
Descriptions of Specific Treatment  
Robotic Assisted Laparoscopic Prostatectomy Procedure 
When a RALP is performed, the patient is brought into the operating room that 
houses the da Vinci robot. The patient is prepped for surgery and sterilized before the 
procedure begins (Tewari et al., 2002). A small incision is made just above the 
bellybutton and a tube-like instrument called a port is inserted into the incision (Tewari 
et al., 2002). Carbon dioxide is pumped into the abdomen through this port to inflate it, 
giving the surgeon more room to maneuver the surgical tools and a better field of vision 
(Tewari et al., 2002). Up to six more incisions are made in the abdomen for additional 
ports—two for the rest of the surgical tools and the rest for the surgical assistant’s tools 
(Tewari et al., 2002). From there, the order of the steps vary, but the structures 
surrounding the bladder and prostate such as the vas deferens, neurovascular bundles, 
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and rectum are dissected away from the prostate so that it can be removed (Tewari et 
al., 2002). The urethra above and below the prostate are severed to free the prostate so it 
can be removed (Tewari et al., 2002). The severed ends of the urethra are connected 
with stitches to the bladder to bridge the gap of the now removed prostate (Tewari et al., 
2002). The prostate is removed from the abdomen in a small baggie, and the skin and 
fascia are sutured closed to complete the procedure (Tewari et al., 2002). 
External Beam Radiation Therapy 
EBRT is produced via a machine that delivers radiation to a specific location in 
the body. For EBRT, placement of the radiation is essential to make sure both the 
cancer cells are all killed, and that the non-cancerous organs (such as the bladder) are 
spared as much radiation damage possible (Zaorsky et al., 1996). OUI uses Image-
Guided Radiotherapy Therapy (IGRT) to help maintain the specific location of radiation 
(Zaorsky et al., 1996). Prior to EBRT, OUI patients have 2 gold fiducial makers placed 
in their prostate. Visualizing these markers with imaging helps create and maintain a 
consistent specific location for radiation to be delivered during each treatment session 
(Zaorsky et al., 1996). The entire radiation treatment is delivered in doses, usually 
lasting about 15 minutes per day for about 8-9 weeks (Zaorsky et al., 1996). The 
treatment course is long because only a small amount of radiation can be safely 
tolerated every day.  
Oregon Urology Institute 
Oregon Urology Institute (OUI) is the largest and most advanced urologic center 
in the Northwest. In 2006, the local hospital McKenzie Willamette purchased a da Vinci 
 
 
10  
robot, which was fairly new technology and on the verge of becoming much more 
prevalent in the medical field. With the procurement of this machine OUI hired Dr. 
David DiMarco, who is a surgeon trained on the use of this robot, to perform RALPs. 
As this was fairly new technology and the RALP was less prevalent, the procedure was 
more expensive and there were issues with insurance covering the cost for patients. To 
determine whether surgeries performed with the da Vinci robot lead to better surgical 
outcomes than conventional methods, OUI developed a Prostate Cancer database. 
Originally, data was collected comparing RRP to RALP in terms of blood loss 
and other direct surgical comparisons to measure whether the RALP had significantly 
better surgical outcomes. Later, Health-Related Quality of Life (HRQOL) 
questionnaires were added to the database to track HRQOL in patients with RRP and 
RALP after treatment. EPIC questionnaires were used to assess urinary, bowel, sexual, 
and hormonal function as well as patient satisfaction. In 2008, this HRQOL protocol 
was extended to radiation patients. OUI has tracked HRQOL data for 11 years for 
prostatectomy patients, and 9 years for EBRT patients.  
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Introduction 
Treating prostate cancer while attempting to maintain a high quality of life in 
terms of urinary and sexual function is difficult, as nerves that supply the urethra and 
penis are contained in neurovascular bundles that run posterior-laterally along the 
prostate (Walsh et al., 1983). Surgical removal or radiation of the prostate can damage 
these nerves and have a severe impact on urinary and sexual function of patients after 
treatment, which can lead to a lower quality of life (Walsh et al., 1983). Quality of life 
for patients being treated for prostate cancer is a major factor in the decision of which 
treatment to use. Poorer quality of life due to incontinence and erectile dysfunction can 
lead to depression, poorer quality of sleep, and lower levels of overall of health (Coyne 
et al., 2008). Thus, assessing which treatment leads to the best quality of life is an 
important factor in the deciding how to treat prostate cancer.  
For cancer that is localized to the prostate, both Robot Assisted Laparoscopic 
Prostatectomy (RALP) and External Beam Radiation Therapy (EBRT) are considered 
acceptable treatments (Schreiber et al., 2015). Patient input is essential in the treatment 
decision, thus randomized-control studies are difficult to perform to determine which 
treatment has better quality of life outcomes. Researchers have heavily relied on 
retrospective studies to assess the benefits of one treatment versus another, but these 
studies often yield no clear distinction. EBRT and RALP are both associated with a 
decline in Health Related Quality of Life (HRQOL) directly after treatment, but thus far 
there is no clear indication as to which is the better treatments in terms of the recovery 
of urinary and sexual function (Miller et al., 2005) (Frank et al., 2007). Many studies 
that investigate this were performed before 2006 when RALP surgical techniques 
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became more widespread, and have only compared Radical Retropubic Prostatectomy 
to EBRT.  This study compares recovery of urinary and sexual function using 
information from the Prostate Cancer HRQOL database in patients that were treated 
with RALP or EBRT.  
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Purpose 
The purpose of this study was to determine if EBRT results in better sexual 
and/or urinary function recovery in patients two years after initial treatment compared 
to RALP. 
 
 
 
14  
Hypothesis 
I hypothesized that the changes in sexual function EPIC scores would indicate 
better sexual function recovery for patients treated with EBRT than RALP. I 
hypothesized that changes in urinary function EPIC scores would indicate better 
recovery of urinary function in patients treated with RALP than EBRT.  
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Methods 
Patient Selection 
This study compared EBRT to RALP, so patients selected for this study were 
good candidates for both EBRT and RALP at the time of their initial treatment. Almost 
all patients are good candidates for EBRT, but not all qualify for RALP. Therefore, only 
EBRT patients that were specifically noted to also qualify for RALP were selected for 
this study.  
Candidacy Criteria for EBRT Patients  
Surgical guidelines denote that patients should live long enough to benefit from 
lack of malignancy. As RALP is an invasive procedure, a patient should have a life 
expectancy of 10 years or more to receive treatment (Lepor, 2000). Although the 
probability that a man 70 years old will live 10 more years after prostatectomy is about 
58% (Lepor, 2000), Oregon Urology Institute physicians do not discriminate treatment 
based on age and will select RALP if a patient has an estimated 10 year life expectancy. 
Thus, patients were selected for this study if it specified in their chart that they are good 
surgical candidates at the time of their initial treatment consultation. Patients selected 
had a Gleason Score of 6-8 indicating that they needed initial treatment. Patients with a 
Gleason score of 9-10 are very high risk and most often receive multiple treatment types 
such as surgery or radiation with hormone(Fowler, Jr et al., 2000). This possibility of 
multiple treatments would confound the study results, so these patients were not 
included. Selected patients had a TNM score in the range of T1a-T3a indicating they 
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still had organ confined prostate cancer in order to be eligible for prostatectomy (Lepor, 
2000).   
Candidacy Criteria for RALP Patients 
Patients selected had a Gleason Score of 6-8 indicating they needed initial 
treatment. Selected patients had a TNM score in the range of T1a-T3a indicating they 
still have organ confined prostate cancer in order to be eligible for prostatectomy 
(Lepor, 2000). Patients who were selected had a form of a nerve sparing procedure 
(Bilateral, Right, Split, etc.) to control for poor erectile function.  
Data Collection 
Sexual and Urinary Function Data 
This study examines differences in sexual and urinary function for EBRT and 
RALP through Oregon Urology Institute’s (OUI) Prostate Cancer Database. 
Measurements for Sexual and Urinary function have been acquired through the 
Expanded Prostate Index Composite (EPIC). EPIC questionnaires inquire about the 
patient’s urinary, bowel, hormonal, and sexual bother and reflects their urinary, bowel, 
hormonal, and sexual function respectively (Wei et al., 2000). The EPIC questionnaires 
relates the scores for each question in a section that are ranked on a 1-5 or 1-4 basis into 
a percentage that gives a summary of the function for that section. Thus if the top score 
is selected by the patient for each question in a section such as urinary function, that 
patient would receive 100 for that section when their EPIC score is calculated. Higher 
scores represent less bother and better function. The scores recorded for sexual and 
urinary function were used in this study, and all other information was omitted. A 
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packet with this questionnaire is sent out to patients willing to participate in the Prostate 
Cancer Database before their treatment, quarterly for the first year, and then annually. 
The 2-year time point was chosen to assess recovery of urinary and sexual function as 
improvement in both generally does not occur past 24 months (Penson et al., 2008) 
(Donovan et al., 2016).  
Treatment Related Information 
Many co-variants were included in this study. Smoking status was determined 
based off of smoking status at time of treatment. Co-morbidities were recorded from 
conditions recorded in patients’ chart at time of treatment. Race was recorded on patient 
reported race in their chart. Use of hormone therapy was determined from listed 
medications on the patient’s chart. Erectile aid use before and at the two year time point 
was determined based off medication lists and notes made in the patient’s chart. Other 
information regarding Gleason Score and other biopsy information was recorded from 
the biopsy pathology report, and the TRUS surgical report. Surgery related information, 
such as procedures performed and diagnostics, were recorded from the prostatectomy 
pathology report and the surgical notes.  
Data De-identification  
Patients were assigned a random three-digit number generated by a random 
series generator. This number allowed for the data of an individual to stay associated 
with an individual outcome. No personal health information or identifiers (such as 
name, birthdate, or surgery dates) were included in the data used for this study. The key 
that connected this three-digit number to the patients was kept secure.  
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Statistical Analysis 
The patients’ clinical presentations were analyzed with Welch’s t-test (two tailed 
t-test with unequal variance). Demographic information, which was included as possible 
confounding variables, was analyzed with Fisher’s exact test. A Wilcoxon rank-sum test 
was used to compare baseline BMI of patients in each treatment group, as there were 
not normal distributions. General Linear Models (GLM) were used to assess significant 
differences between treatment groups, and identify if any variables were confounding 
the relationship between treatment groups and EPIC scores for Urinary and Sexual 
function. 
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Results 
Table 1 shows the clinical presentations of each treatment group. The patients in 
both treatment groups were largely similar. One statistically significant difference was 
the TNM Stage between the two treatment groups. The RALP treatment group had a 
slightly higher average TNM staging of T2b than the EBRT group’s T2a.  
Patient Demographics 
  EBRT    RALP   
Average Mode   Average Mode   
Age at start of 
tx (yr) 
66 
SD: 7 
59 
  
  64 
SD: 6.8 
68 
  
  
    
PSA Level 
(ng/mL) 
5.7 
SD: 3 
5.5 
  
  6.1 
SD: 4.3 
5.5 
  
  
    
Prostate Size 
(mL) 
43 
SD: 15.8 - 
  39.8 
SD: 20.2 
33 
  
  
    
Gleason Score  6.4 SD: 0.5 
6 
  
  6.6 
SD: 0.7 
6 
  
  
    
1st Grade 3.1 SD: 0.3 
3 
  
  3.2 
SD: 0.4 
3 
  
  
    
2nd Grade 3.3 SD: 0.5 
3 
  
  3.4 
SD: 0.5 
3 
  
  
    
Biopsies (% of 
positive 
samples) 
35.6 
SD: 22.4 
25 
  
  
35 
SD: 20.4 
33 
  
  
    
Highest % of 
Cores 
49 
SD: 28.7 
80 
  
  46 
SD: 29.9 
80 
  
  
    
Clinical TNM 
Stage*  t2a t1c 
  t2b t2c       
BMI 29.1 SD: 4.4 -   
27.9 
SD: 3.9 25.9 
 
  
Table 1: Comparison of Clinical Presentations for EBRT and RALP Patients 
*Statistically significant with Welch’s T-test p< .05. 
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Fisher’s exact test revealed significant differences in the amount of cardiac 
disease between treatment groups. The EBRT group had more instances of cardiac 
disease, with 41% of the patients with cardiac disease. This prevalence of a disease, 
which influences the patient’s overall health, denotes that the EBRT patient group was 
generally less healthy than the RALP group. Fisher’s exact test revealed statistically 
significant differences in the number of patients treated with hormone therapy between 
groups during the time interval this study analyzed. The EBRT group had more patients 
(16% vs. 1%) treated with hormone therapy within the two-year interval post initial 
treatment. As there is decreased libido as well as other symptoms related to the use of 
hormone therapy, the patient’s sexual function EPIC scores could be affected by this 
treatment. The demographic categories of race and use of erectile aid were not included 
in the GLM analysis due to an unacceptable amount of missing data.    
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 Number of Patients (%)  
 EBRT RALP  Patients Included 
Total number of patients 32 104  
Lost to follow up 0 (0%) 7 (6.7%)  
Deceased 0 (0%) 2 (2%)  
Radiation after initial tx 0 (0%) 10 (10%)  
Pt w/ family history of 
prostate cancer 11 (34%) 32 (31%)  
Comorbidities** 
No comorbidities 12 (38%) 94 (90%)  
Cardiac disease** 13 (41%) 2 (2%)  
Hypertension 1 (3%) 5 (5%)  
Arterial disease 0 (0%) 1 (1%)  
Smoking Status* 
Pt never smoked 12 (38%) 58 (56%)  
Pt current smoker 2 (6%) 1 (1%)  
Pt former smoker 18 (56%) 39 (38%)  
Race° 
Alaskan native 1 (3%) 0 (0%)  White 23 (72%) 65 (63%)  
Race not reported 8 (25%) 39 (37%)  
Erectile Aid Use°  
No Erectile aid use 
before tx 6 (19%) 92 (88%)  
Erectile aid use before tx 26 (81%) 11 (11%)  
Erectile aid use not 
reported before tx 0 (0%) 1 (.01%)  
No Erectile aid after tx 22 (69%) 32 (30%)  
Erectile aid use after tx  9 (28%) 50 (48%)  
Erectile aid use not 
reported after tx 1 (3%) 22 (21%)  
Hormone Therapy*  
Received hormone 
therapy 5 (16%) 1 (1%)  
No hormone therapy 27 (84%) 103 (99%)  
Table 2: Comparison of Covariates in Treatment Patient Population 
*Indicates statistically significant differences between the treatment groups p < .05 
** Indicates statistical significant differences between treatment groups p < .001    
° Indicates variable not included in analysis due to missing data 
 
 
22  
Statistical Tests 
Figure 1 shows the distribution of urinary change scores for EBRT and RALP. 
The unadjusted GLM model illustrated in Table 3 had an overall F value of 0.52. This F 
value is not less than 0.05, suggesting that this model is not a successful fit so an 
adjusted model was run.  
 
Figure 1: Distribution of Urinary EPIC Score Change  
In this figure, 0 denotes baseline. As 2yr scores were subtracted from pre-treatment 
scores, negative scores indicate improvement from initial urinary function and positive 
scores represent a worsening from initial urinary function. 
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Unadjusted GLM 
Model   
      Mean  R
2  Pr  > F  -1.22  0.003  0.52  
      
  Estimate  Pr > |t|  
      Intercept  -1.79  0.35  EBRT  2.71  0.52  RALP  0.00    
      Table 3: Reported Values from the Urinary Function Unadjusted GLM Model 
 
Table 4 shows the reported values of the fully adjusted GLM model that 
included possible confounding variables. The variables that were found to confound the 
association (to have an effect on change in urinary EPIC score independent of treatment 
group) of study variables were cardiac disease, arterial disease, age, BMI, smoking, 
hypertension, and hormone treatment. None of these variables were found to modify the 
association (act in association with treatment group to affect urinary EPIC score) of 
study variables. The F-value for the fully adjusted GLM model was 0.0076 indicating a 
good fitting model. The R2 value generated by this analysis was 0.18. This indicates that 
the treatment groups and all of the confounding variables explain 18% of the variation 
in urinary change for all the patients included in this analysis.  EBRT had 4.45 greater 
increase in urinary change score than RALP, indicating a worsening in urinary function 
from baseline (as positive values represent a worsening in function). This association is 
not statistically significant with a p-value of 0.40. Thus, no statistically significant 
change was detected between urinary score change for EBRT and RALP. The mean of 
all patients included in the GLM procedure was -0.81. As this value is negative, it 
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shows that there was a general improvement of urinary function in men treated for 
prostate cancer with either treatment.  
      
  
Adjusted GLM 
Model    
      Mean  R^2  Pr > F  -0.81  0.18  0.0076  
      
  Estimate  Pr > |t|  
      Intercept  10.19  0.61  EBRT  4.45  0.41  RALP  0.00    
      Table 4: Reported Values from the Urinary Function Fully Adjusted GLM Model 
 
Figure 2 shows the unadjusted GLM model of change in sexual function from 
pre-treatment to 2 years post treatment. The F-value reported in Table 5 for this model 
was 0.012 indicating the model was a good fit. The R2 value is 0.05 indicating, 5% of 
the variation in change sexual function from pre-treatment to 2 years is explained by 
type of treatment. The difference in change for patients undergoing EBRT was -11.9, 
which was statistically different (p = 0.01). As negative numbers represent an 
improvement in sexual function from baseline, this indicates that EBRT patients had 
better sexual function than RALP patients. 
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Figure 2: Distribution of Sexual EPIC Score Change   
In this figure, 0 denotes baseline. As 2yr scores were subtracted from pre-treatment 
scores, negative scores indicate improvement from initial urinary function and positive 
scores represent a worsening from initial urinary function. *Indicates a statistically 
significant difference (p < 0.05) 
 
      
  
Unadjusted GLM 
Model   
      Mean  R^2  Pr > F  15.94  0.052  0.012  
      
  Estimate  Pr > |t|  
      Intercept  18.34  <.0001  EBRT  -11.88  0.012  RALP  0.00    
      Table 5: Reported Values from Sexual Function GLM Unadjusted Model 
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The fully adjusted GLM procedure was performed which included hormone 
treatment in the analysis, as it was found to confound the relationship between treatment 
group and change in EPIC sexual function score. It was found that hormone treatment 
did not modify the association (act in conjunction with type of treatment) to affect 
change in EPIC score. The F value for the fully adjusted GLM model shown in Table 6 
was 0.028, demonstrating a model of good fit. The R2 value was 0.06, which indicates 
that treatment group can explain 6% of the variation in change in sexual function from 
baseline to 2 years. The difference in change between the EBRT patients and the RALP 
patients was -10.4, which is a statistically significant difference (p = 0.04).  As negative 
numbers represent an increase in function, EBRT patients have better sexual function 
than RALP patients.  
 
      
  
Adjusted GLM 
Model    
      Mean  R^2  Pr > F  15.94  0.06  0.028  
      
  Estimate  Pr > |t|  
      Intercept  18.43  <.0001  EBRT  -10.42  0.036  RALP  0.00    
      Table 6: Reported Values from Sexual Function Fully Adjusted GLM Model 
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Discussion 
This study compared RALP to EBRT in terms of urinary and sexual function 
change from pre-treatment. The purpose of this comparison was to determine if either 
treatment provided better outcomes for patients. It was hypothesized that RALP patients 
would have better improvement urinary function, and EBRT would have better 
improvement sexual function. 
 No significant difference was identified between the treatments for change in 
urinary function at the two-year time point. This indicates that neither is superior at 
preserving urinary function. The mean of all of the patients included in the analysis of 
urinary function was negative. This indicates that in general, all patients who undergo 
treatment for prostate cancer have improved urinary function from before their initial 
treatment. This study’s finding of no significant difference between urinary change and 
treatment groups does not coincide with a study performed by Chien in 2017.  This 
study found that urinary function was significantly worse in RALP patients compared to 
other treatments such as EBRT (Chien et al., 2017). As there are still few studies that 
compare RALP to EBRT these conflicting findings cannot be reconciled.  
This study also uncovered an interesting finding that could help explain 
variation in urinary change scores for patients treated for prostate cancer. The analysis 
of urinary function found that arterial disease is significantly associated with a greater 
urinary change score compared to no artery disease (p  = 0.001). This suggests that 
artery disease may be a better predictor of loss of urinary function after prostate cancer 
treatment than treatment type. Further investigation into this relationship between 
urinary function and arterial disease is warranted to distinguish if arterial disease should 
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be taken into account in the treatment decisions for patients when attempting to 
preserve urinary function.  
A significant difference was found in the change in sexual function scores 
between treatment groups. The EBRT patients had a difference in change of -10.4 from 
the RALP patients. As negative numbers indicate an improvement in function, EBRT 
patients’ sexual function improved when compared to RALP patients (p = 0.04). This 
indicates that EBRT is the superior treatment in the preservation sexual function. These 
findings agree with Chein’s 2017 study that found EBRT patients had better sexual 
function when compared to RALP patients.  
This study has limitations that affect the conclusions that are drawn. As this 
study was performed with self-report EPIC questionnaires, there is the chance that the 
answers the subjects provided are not an accurate representation of their urinary or 
sexual function. This study also contained a much smaller sample size of EBRT patients 
compared to RALP patients. This was due to extensive missing data in pre-treatment 
scores for patients treated with EBRT. This missing data likely results from differences 
in EPIC packet distribution practices at the location where patients receive EBRT. This 
study also relied heavily on data in patient charts for assessment of cofounding 
variables. If these charts were not updated or did not contain the information gathered 
by this study, the affect of these cofounding variables determined in this study could be 
inaccurate. As was mentioned, there was extensive missing data in erectile aid use and 
race. A study that was designed to collect this information in a more reliable way, rather 
than relying on information included in a patient’s chart, would be able to assess 
cofounding variables to a more accurate degree. The diversity of patients is also a 
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limitation in this study because the demographic was largely white men. A study that 
included a larger representation of the diversity or the populations would be able to 
draw more extensive conclusions.  
This is one of the first studies that compare RALP to other treatments. More 
studies that compare RALP to other treatments are needed to assess which treatment 
will best suit patient needs. As use of erectile aids was not able to be included in this 
analysis due to extensive missing data, studies that analyze the role of erectile aid use in 
sexual function change after prostate cancer treatment should be conducted to evaluate 
how they affect the change in sexual function in relation to treatment type. 
This study will add to the growing field of knowledge of the benefits of different 
prostate cancer treatments. It supports that EBRT is a better therapy for preserving 
sexual function, and informs that either treatment will preserve urinary function to a 
similar degree.  
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Conclusion 
Health related quality of life in terms of urinary and sexual function varies by 
treatment. EBRT was a better treatment for preserving sexual function, but neither 
treatment is better for preserving urinary function in this study. This study adds to the 
information about different prostate cancer treatments, and allows for the possibility 
that treatments can be specified to a patient’s needs to create the best quality of life after 
surgery that can be achieved.    
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Appendix A: Statistical Analysis Report 
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